TY - JOUR
T1 - Colorectal cancer with residual polyp of origin
T2 - A model of malignant transformation
AU - Druliner, Brooke R.
AU - Rashtak, Shahrooz
AU - Ruan, Xiaoyang
AU - Bae, Taejeong
AU - Vasmatzis, Nikolaos
AU - O’Brien, Daniel
AU - Johnson, Ruth
AU - Felmlee-Devine, Donna
AU - Washechek-Aletto, Jill
AU - Basu, Nivedita
AU - Liu, Hongfang
AU - Smyrk, Thomas
AU - Abyzov, Alexej
AU - Boardman, Lisa A.
N1 - Funding Information:
Funding: This work was supported by the National Cancer Institute at the National Institutes of Health ( R01 CA170357 ) and the Clinical Core of the Mayo Clinic Center for Cell Signaling in Gastroenterology ( P30DK084567 ). This publication was also made possible by CTSA grant number UL1 TR000135 from the National Center for Advancing Translational Sciences , a component of the National Institutes of Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the National Institutes of Health.
Publisher Copyright:
© 2016 The Authors.
PY - 2016/8
Y1 - 2016/8
N2 - The majority of colorectal cancers (CRCs) arise from adenomatous polyps. In this study, we sought to present the underrecognized CRC with the residual polyp of origin (CRC RPO+) as an entity to be utilized as a model to study colorectal carcinogenesis. We identified all subjects with biopsy-proven CRC RPO+ that were evaluated over 10 years at Mayo Clinic, Rochester, MN, and compared their clinical and pathologic characteristics to CRC without remnant polyps (CRC RPO−). Overall survival and disease-free survival overlap with an equivalent hazard ratio between CRC RPO+ and RPO− cases when age, stage, and grade are adjusted. The somatic genomic profile obtained by whole genome sequencing and the gene expression profiles by RNA-seq for CRC RPO+ tumors were compared with that of age -and gender-matched CRC RPO− evaluated by The Cancer Genome Atlas. CRC RPO+ cases were more commonly found with lower-grade, earlier-stage disease than CRC RPO−. However, within the same disease stage and grade, their clinical course is very similar to that of CRC RPO−. The mutation frequencies of commonly mutated genes in CRC are similar between CRC RPO+ and RPO− cases. Likewise, gene expression patterns are indistinguishable between the RPO+ and RPO− cases. We have confirmed that CRC RPO+ is clinically and biologically similar to CRC RPO− and may be utilized as a model of the adenoma to carcinoma transition.
AB - The majority of colorectal cancers (CRCs) arise from adenomatous polyps. In this study, we sought to present the underrecognized CRC with the residual polyp of origin (CRC RPO+) as an entity to be utilized as a model to study colorectal carcinogenesis. We identified all subjects with biopsy-proven CRC RPO+ that were evaluated over 10 years at Mayo Clinic, Rochester, MN, and compared their clinical and pathologic characteristics to CRC without remnant polyps (CRC RPO−). Overall survival and disease-free survival overlap with an equivalent hazard ratio between CRC RPO+ and RPO− cases when age, stage, and grade are adjusted. The somatic genomic profile obtained by whole genome sequencing and the gene expression profiles by RNA-seq for CRC RPO+ tumors were compared with that of age -and gender-matched CRC RPO− evaluated by The Cancer Genome Atlas. CRC RPO+ cases were more commonly found with lower-grade, earlier-stage disease than CRC RPO−. However, within the same disease stage and grade, their clinical course is very similar to that of CRC RPO−. The mutation frequencies of commonly mutated genes in CRC are similar between CRC RPO+ and RPO− cases. Likewise, gene expression patterns are indistinguishable between the RPO+ and RPO− cases. We have confirmed that CRC RPO+ is clinically and biologically similar to CRC RPO− and may be utilized as a model of the adenoma to carcinoma transition.
UR - http://www.scopus.com/inward/record.url?scp=84983382754&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84983382754&partnerID=8YFLogxK
U2 - 10.1016/j.tranon.2016.06.002
DO - 10.1016/j.tranon.2016.06.002
M3 - Article
AN - SCOPUS:84983382754
SN - 1944-7124
VL - 9
SP - 280
EP - 286
JO - Translational Oncology
JF - Translational Oncology
IS - 4
ER -